A few years back, Dr. Redford Williams made a change in his life that might
not seem like much. But he knew better.

"It was big," recalls Williams, who is clued in because he is a behavioral
medicine specialist at Duke University. For years he has been studying such
topics as how anger and hostility affect heart disease.

What did Williams do? He simply decided that on Sunday mornings he would
stop fretting about how long it might take his wife, Virginia, to get ready

A secondary analysis of the Women’s Health Study was conducted to evaluate
whether vitamin E supplementation reduced the risk of venous thromboembolism. 
According to a 2008 U.S. Surgeon General’s report, at least 100,000 deaths in the
United States result from deep vein thrombosis and pulmonary embolism induced by
venous thromboembolism.  Women 45 years and older (n=39,876) were randomized
to 600 IU vitamin E (α-tocopherol) or a placebo every other day.  Genotyping for

Newswise — A new study finds that many cancer patients would prefer to receive information over emotional aid from support groups, although – over time – their needs could change.

Although clinicians and others frequently advise cancer patients to join support groups to deal with the psychological consequences of their diagnosis, a minority of cancer patients actually joins.

Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future.

Multiple myeloma is a type of cancer affecting the blood plasma cells in bone marrow responsible for producing antibodies. Each year, nearly 14,600 Americans are diagnosed with multiple myeloma. The severity ranges from low-risk to high-risk and makes all the difference in patients' odds of survival.

Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future.